Use of the ELITE response approach to identify new cancer targets and therapeutic antibodies; development of a new biological product that hijacks the uptake of essential amino acids to specifically deliver cytotoxic payloads for the treatment of colon cancer.
Abstract:
This new project, led by a multidisciplinary consortium, aims to revolutionize the treatment of metastatic colorectal cancer (CRC), especially in patients who do not respond to current immunotherapies. The approach focuses on developing a new ADC (Antibody Drug Conjugate) targeting LAT1, a receptor highly expressed in colorectal tumors, particularly those with KRAS mutations and chemotherapy resistance.
The consortium brings together the expertise of Dr. Manuel Palacín’s group (IRB), which has over 30 years of research on transporters such as LAT1/CD98hc, Leitat’s antibody discovery and validation technology, and Ona Therapeutics’ clinical knowledge in biological therapies, specializing in the development of antibodies, bispecifics, and ADCs.
The project will develop and select the best antibodies using proprietary platforms and patient libraries, as well as employ PDX models and patient-derived organoids to test treatment efficacy. The combination of scientific knowledge, advanced technological platforms, and preclinical models positions this project as a high-impact proposal to improve the prognosis of patients with advanced colorectal cancer.
Leitat’s Role in the Project:
Leitat will act as a beneficiary partner in the ADC-LAT1 project.
Project’s Budget: 2.242.953,60€
Financial Framework: Proyectos de colaboración público-privada 2023
Start Date: 01/11/2024
Leitat’s Budget: 550.088,75€
Contract Number: CPP2023-010554
End Date: 31/10/2027
Partners:
COORDINATOR:
CPP2023-010554 project funded by:
